Skip to main content

Table 2 Univariable and multivariable analyses of TTP

From: Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib

 

Univariable analysis

Multivariable analysis

Variable

N

HR (95% CI)

p value

HR (95% CI)

p value

Age, years

< 65

125

1

0.736

–

–

≥65

26

1.08 (0.69–1.70)

 

–

–

Sex

Male

137

1

0.806

–

–

Female

14

0.93 (0.51–1.69)

 

–

–

ECOG PS

0

52

1

0.158

–

–

1–2

99

1.31 (0.90–1.90)

 

–

–

Etiology

HBV

134

1

0.403

–

–

Non-HBV

17

1.26 (0.73–2.17)

 

–

–

Child-Pugh class

A

140

1

0.595

–

–

B

11

1.20 (0.68–2.38)

 

–

–

BCLC stage

B

5

1

0.191

–

–

C

146

2.15 (0.68–6.76)

 

–

–

MVI

No

88

1

0.127

–

–

Yes

63

1.32 (0.93–1.87)

 

–

–

EHS

No

15

1

0.090

–

–

Yes

136

1.71 (0.92–3.20)

 

–

–

AFP (ng/mL)

< 200

73

1

0.008

1

0.092

≥200

77

1.62 (1.14–2.31)

 

1.37 (0.95–1.98)

 

cfDNA (ng/μL)

≤0.71a)

76

1

0.003

1

0.245

> 0.71a)

75

1.71 (1.20–2.44)

 

1.27 (0.85–1.88)

 

I-score

≤1637a)

76

1

< 0.0001

1

0.011

>1637a)

75

2.09 (1.46–3.00)

 

1.71 (1.13–2.58)

 
  1. HR hazard ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, HBV hepatitis B virus, BCLC Barcelona Clinic Liver Cancer, MVI macroscopic vascular invasion, EHS extrahepatic spread, AFP alpha fetoprotein, cfDNA cell-free DNA
  2. a)Median value